David, Valentin

Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling

Martin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J. Q., & Quarles, L. D. (2011) · The FASEB Journal

Parathyroid Disorders and TreatmentsAlkaline Phosphatase Research Studies

Cited by 254

Degradation of MEPE, DMP1, and release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) are directly responsible for defective mineralization in HYP

Martin, A., David, V., Laurence, J. S., Schwarz, P. M., Lafer, E. M., Hedge, A.-M., & Rowe, P. S. N. (2008) · Endocrinology

Parathyroid Disorders and TreatmentsBone and Dental Protein Studies

Cited by 173

Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor–I pathway

Martin, A., David, V., Malaval, L., Lafage-Proust, M.-H., Vico, L., & Thomas, T. (2007) · Endocrinology

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 111

Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator

David, V., Martin, A., Hedge, A.-M., & Rowe, P. S. N. (2009) · Endocrinology

Parathyroid Disorders and TreatmentsAlkaline Phosphatase Research Studies

Cited by 106

DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease

Dussold, C., Gerber, C., White, S., Wang, X., Qi, L., Francis, C., Capella, M., Courbon, G., Wang, J., Li, C., et al. (2019) · Bone Research

Parathyroid Disorders and TreatmentsBone Metabolism and Diseases

Cited by 96